Molecular diagnostics startup Swift Biosciences Inc. has pulled in a $3 million Series A investment.
The Ann Arbor, Michigan-based company will sell molecular biology reagents, which help scientists and doctors conduct genetic tests to identify whether patients are susceptible to specific diseases.
Reagents are chemicals used in lab settings to determine whether a chemical reaction has occurred, or to bring about a reaction.
The round was led by Houston-based DFJ Mercury, and included participation from several individual investors.
Swift’s CEO, David Olson, is the former chief scientific officer for Ann Arbor-based device startup Accuri Cytometers, which recently raised $6 million.
Tech accelerator DreamIt Ventures launches minority-focused program
Is the early stage funding valley of death a myth?
Teleradiology group Foundation adds another $1M in funding
CMXI’s Aldagen acquisition is no exit; stem cell payoff is still down the road
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
No comments yet.
Post a Comment